83
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Trends in Endogenous Endophthalmitis in Rural and Urban Settings in the United States

, &
Pages 300-306 | Received 04 Jan 2021, Accepted 22 Jun 2022, Published online: 17 Jul 2022
 

ABSTRACT

Purpose

The objective of this study is to explore and compare trends in urban and rural cases of endogenous endophthalmitis (EE) in the United States.

Methods

This study utilizes data from the 2002–2014 National Inpatient Sample (NIS) Database. Disease diagnoses and procedures were identified using codes from the International Classification of Diseases, Ninth Revision (ICD-9). Cases of EE were defined as cases of endophthalmitis in the setting of bacteremia or candidemia without a recent history of ocular trauma. The NIS Database defines urban and rural hospitals based on the hospital county’s population statistics. Statistical analysis was performed using IBM SPSS 23.

Results

We identified 8255 cases of EE. Of these cases, 523 (6.3%) occurred in rural areas; 7733 (93.7%) occurred in urban areas. Of the cases of EE, 7692 (93.2%) were bacterial EE, 412 (5.0%) were candida EE, and 151 (1.8%) were mixed EE. Candida EE was observed in 1.7% of rural cases and 5.2% of urban cases (p < .001). Pars plana vitrectomies were performed more often in urban hospitals than in rural hospitals (11.5% vs. 2.9%; p < .001).

Conclusion

Endogenous endophthalmitis remains a rare but devastating ocular infection. In this study, we have demonstrated that there are important differences in cases of EE that present to urban and rural hospitals. Future investigations into these differences in patient demographics, source/systemic infections, and hospital courses may allow clinicians and hospitals to develop a more targeted approach to treating EE based on the type of community from which the patient presents.

Financial support

There was no financial support or funding for this study.

Disclosure statement

  1. Aditya Uppuluri does not have any financial disclosures.

  2. Marco A. Zarbin is a consultant for Boehringer Ingelheim, Genentech/Roche, Frequency Therapeutics, Iduna, Iveric Bio, LIfe Biosciences, Novartis Pharma AG, Ophthotech, Perfuse Therapeutics, and Selphagy. He owns equity in Frequency Therapeutics, Iveric Bio, and NVasc (Co-Founder).

  3. Neelakshi Bhagat does not have any financial disclosures.

Prior submissions/publications

This manuscript has not been published anywhere previously, and it is not in simultaneous consideration for publication in another journal. The manuscript has not been submitted to any journal prior to this current submission.

Data availability

This study utilizes data contained in the National Inpatient Sample Database, which is available for purchase on the Healthcare Cost and Utilization Project’s website.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 740.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.